ESG Tracker
  • Companies
  • Rankings
  • Portfolios
  • My Portfolios
  • Log In Log Out
  • Contact

← Back to search

Precigen, Inc.

PGEN · NASDAQ

Research and Development in Biotechnology · US

Precigen is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. The Company's technologies enable to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated unique therapies toward clinical proof-of-concept and commercialization.

Products and Services
  • Company Search
  • Rankings
  • Portfolios
About ESG Tracker
  • FAQ
Legal & Security
  • Disclosures
  • Privacy Policy
Contact
  • Contact Us
ESG Tracker

ESG Tracker is for informational purposes only and does not constitute investment advice. The operator of this site is not a registered investment advisor. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.

Public ESG data sourced from Public Company ESG Ratings Dataset by esgcompare.org, licensed under CC BY-NC-SA 4.0. This site is non-commercial and for informational purposes only.